ÂÜÀòÂÒÂ×

Dr. Nejadnik has more than two decades of productive experience in large pharma and small biotech companies, as well as in academic institutions, leading research teams and organizations in developing and marketing biologics, small molecules and genetically modified cell therapy. He led the programs from early phase to registration trials, with successful BLA/NDA/MAA submissions and market launch. He was teaching faculty at University of California and Stanford University. He held multiple key roles at Johnson & Johnson working on numerous compounds in early and late stage registrational trials in Alzheimer diseases immunology, autoimmune disorders, hematology and oncology. After more than seven years of highly successful work, he joined Jazz Pharmaceuticals as Executive Director, where he led the clinical team towards an approved biologic license application (BLA) and was the lead of medical affairs division, for the launch of the FDA approved drugs. Dr. Nejadnik was –Chief Medical Officer, at Galena Biopharma and later at Eureka Therapeutics, where he was responsible for all clinical development programs, regulatory, cell manufacturing and medical affairs. Dr. Nejadnik graduated from the University of Louvain in Belgium for both his undergraduate degree in premedical studies, graduating Summa Cum Laude, and his medical degree (M.D.), graduating Magna Cum Laude. He completed his post graduate fellowships at Cornell University and Johns Hopkins University.